The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics

Overview

Journal Mol Diagn Ther

Specialties Molecular Biology
Pathology
Pharmacology

Date 2023 Jan 19

PMID 36656511

Authors

Dhaneshree Bestinee Naidoo

Anil Amichund Chuturgoon

Affiliations

Soon will be listed here.

Abstract

The infectious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent for coronavirus disease 2019 (COVID-19). Globally, there have been millions of infections and fatalities. Unfortunately, the virus has been persistent and a contributing factor is the emergence of several variants. The urgency to combat COVID-19 led to the identification/development of various diagnosis (polymerase chain reaction and antigen tests) and treatment (repurposed drugs, convalescent plasma, antibodies and vaccines) options. These treatments may treat mild symptoms and decrease the risk of life-threatening disease. Although these options have been fairly beneficial, there are some challenges and limitations, such as cost of tests/drugs, specificity, large treatment dosages, intravenous administration, need for trained personal, lengthy production time, high manufacturing costs, and limited availability. Therefore, the development of more efficient COVID-19 diagnostic and therapeutic options are vital. Nanobodies (Nbs) are novel monomeric antigen-binding fragments derived from camelid antibodies. Advantages of Nbs include low immunogenicity, high specificity, stability and affinity. These characteristics allow for rapid Nb generation, inexpensive large-scale production, effective storage, and transportation, which is essential during pandemics. Additionally, the potential aerosolization and inhalation delivery of Nbs allows for targeted treatment delivery as well as patient self-administration. Therefore, Nbs are a viable option to target SARS-CoV-2 and overcome COVID-19. In this review we discuss (1) COVID-19; (2) SARS-CoV-2; (3) the present conventional COVID-19 diagnostics and therapeutics, including their challenges and limitations; (4) advantages of Nbs; and (5) the numerous Nbs generated against SARS-CoV-2 as well as their diagnostic and therapeutic potential.

Citing Articles

Systematic surveillance of SARS-CoV-2 reveals dynamics of variant mutagenesis and transmission in a large urban population.

Aynaud M, Caldwell L, Al-Zahrani K, Barutcu S, Chan K, Obersterescu A Nat Commun. 2024; 15(1):10795.

PMID: 39738001 PMC: 11685962. DOI: 10.1038/s41467-024-55031-1.

Nanobody engineering: computational modelling and design for biomedical and therapeutic applications.

El Salamouni N, Cater J, Spenkelink L, Yu H FEBS Open Bio. 2024; 15(2):236-253.

PMID: 38898362 PMC: 11788755. DOI: 10.1002/2211-5463.13850.

Single domain antibodies from camelids in the treatment of microbial infections.

De Greve H, Fioravanti A Front Immunol. 2024; 15:1334829.

PMID: 38827746 PMC: 11140111. DOI: 10.3389/fimmu.2024.1334829.

Aptamers and Nanobodies as New Bioprobes for SARS-CoV-2 Diagnostic and Therapeutic System Applications.

Park K, Park T, Lee J, Hwang S, Choi A, Pack S Biosensors (Basel). 2024; 14(3).

PMID: 38534253 PMC: 10968798. DOI: 10.3390/bios14030146.

SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.

Pavan M, Bok M, Betanzos San Juan R, Malito J, Marcoppido G, Franco D Viruses. 2024; 16(2).

PMID: 38399961 PMC: 10892724. DOI: 10.3390/v16020185.

References

Badgujar K, Badgujar V, Badgujar S . Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges. Diabetes Metab Syndr. 2020; 14(5):1361-1376. PMC: 7371592. DOI: 10.1016/j.dsx.2020.07.022. View

Kirtipal N, Bharadwaj S, Kang S . From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genet Evol. 2020; 85:104502. PMC: 7425554. DOI: 10.1016/j.meegid.2020.104502. View

Bchetnia M, Girard C, Duchaine C, Laprise C . The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020; 13(11):1601-1610. PMC: 7402212. DOI: 10.1016/j.jiph.2020.07.011. View

Guttler T, Aksu M, Dickmanns A, Stegmann K, Gregor K, Rees R . Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. EMBO J. 2021; 40(19):e107985. PMC: 8420576. DOI: 10.15252/embj.2021107985. View

Konyak B, Sharma M, Kharia S, Pandey R, Chang C . A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies. Vaccines (Basel). 2022; 10(9). PMC: 9503441. DOI: 10.3390/vaccines10091468. View

van Kasteren P, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A . Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol. 2020; 128:104412. PMC: 7206434. DOI: 10.1016/j.jcv.2020.104412. View

Stefan M, Light Y, Schwedler J, McIlroy P, Courtney C, Saada E . Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. MAbs. 2021; 13(1):1958663. PMC: 8344751. DOI: 10.1080/19420862.2021.1958663. View

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

Schoof M, Faust B, Saunders R, Sangwan S, Rezelj V, Hoppe N . An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020; 370(6523):1473-1479. PMC: 7857409. DOI: 10.1126/science.abe3255. View

10.

Zupancic J, Schardt J, Desai A, Makowski E, Smith M, Pornnoppadol G . Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS-CoV-2 Variants. Adv Ther (Weinh). 2021; 4(8):2100099. PMC: 8420545. DOI: 10.1002/adtp.202100099. View

11.

Zebardast A, Hosseini P, Hasanzadeh A, Latifi T . The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. Mol Biol Rep. 2021; 49(1):647-656. PMC: 8514607. DOI: 10.1007/s11033-021-06819-7. View

12.

Pymm P, Adair A, Chan L, Cooney J, Mordant F, Allison C . Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021; 118(19). PMC: 8126837. DOI: 10.1073/pnas.2101918118. View

13.

Liang H, Wu Y, Yau V, Yin H, Lowe S, Bentley R . SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. Vaccines (Basel). 2022; 10(9). PMC: 9504858. DOI: 10.3390/vaccines10091538. View

14.

Fernandes Q, Inchakalody V, Merhi M, Mestiri S, Taib N, El-Ella D . Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022; 54(1):524-540. PMC: 8843115. DOI: 10.1080/07853890.2022.2031274. View

15.

Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K . COVID-19 (Novel Coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci. 2020; 24(4):2006-2011. DOI: 10.26355/eurrev_202002_20378. View

16.

Girt G, Lakshminarayanan A, Huo J, Dormon J, Norman C, Afrough B . The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein. R Soc Open Sci. 2021; 8(9):211016. PMC: 8483265. DOI: 10.1098/rsos.211016. View

17.

Maniruzzaman M, Islam M, Ali M, Mukerjee N, Maitra S, Kamal M . COVID-19 diagnostic methods in developing countries. Environ Sci Pollut Res Int. 2022; 29(34):51384-51397. PMC: 9135468. DOI: 10.1007/s11356-022-21041-z. View

18.

Alhamid G, Tombuloglu H, Rabaan A, Al-Suhaimi E . SARS-CoV-2 detection methods: A comprehensive review. Saudi J Biol Sci. 2022; 29(11):103465. PMC: 9512523. DOI: 10.1016/j.sjbs.2022.103465. View

19.

Ferre V, Peiffer-Smadja N, Visseaux B, Descamps D, Ghosn J, Charpentier C . Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain Med. 2021; 41(1):100998. PMC: 8660660. DOI: 10.1016/j.accpm.2021.100998. View

20.

Mistry D, Wang J, Moeser M, Starkey T, Lee L . A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2. BMC Infect Dis. 2021; 21(1):828. PMC: 8371300. DOI: 10.1186/s12879-021-06528-3. View